[
    [
        {
            "time": "2018-04-15",
            "original_text": "Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release",
            "features": {
                "keywords": [
                    "analysts",
                    "Sanofi",
                    "earnings release"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-20",
            "original_text": "A Review of Novo Nordisk’s Modern Insulin",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "modern insulin",
                    "review"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A Review of Novo Nordisk’s Modern Insulin",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-25",
            "original_text": "Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "new-generation insulins",
                    "growth driver"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "Novo Nordisk’s Xultophy Expected to See High Growth in 2018",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Xultophy",
                    "high growth"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk’s Xultophy Expected to See High Growth in 2018",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]